Low-dose prednisolone significantly improves pain symptoms and function in hand osteoarthritis

The results of the low-dose prednisolone in patients with hand osteoarthritis (HOPE) study presented today at the Annual European Congress of Rheumatology (EULAR 2019) show that low-dose prednisolone significantly improves pain and function in patients with painful hand osteoarthritis.

Hand osteoarthritis is a common joint disease. It is characterised by stiff and painful joints. Given the burden of disease, there is a need for effective therapeutic options.

Treatments are currently limited to topical and oral non-steroidal anti-inflammatory drugs (NSAIDs) to relieve . However, studies have shown that synovial inflammation is often present in hand osteoarthritis and it is this inflammation that is a main determinant of pain and radiographic disease progression, identifying synovitis as a possible target of treatment. , Prednisolone is a glucocorticoid used to reduce inflammation and has been used in such as rheumatoid arthritis, polymyalgia, lupus and vasculitis for a long time. However, glucocorticoid use is currently not recommended in patients with hand osteoarthritis due to a previous lack of evidence.

"Hand osteoarthritis is a common musculoskeletal disease, with prevalence rising steeply with increasing age," said Professor John D. Isaacs, Chairperson of the Abstract Selection Committee, EULAR. "Oral glucocorticoid therapy was not included in the recent treatment guidelines update due to limited conflicting data, therefore we welcome these positive results that provide further, controlled evidence in this area."

Results presented today demonstrate that (10mg) provides a significant improvement in pain with an average -16.5 point difference in VAS finger pain (95% confidence interval (CI); -26.1 to -6.9) and a -3.5 point difference in AUSCAN pain* (95% CI; -4.9 to -2.1, p<0.001). In addition, 72% vs. 33% of patients treated with prednisolone and placebo respectively were classified as responders using the OMERACT-OARSI responder criteria. Prednisolone was shown to significantly improve function with an adjusted mean between-group difference of -3.7 points in AUSCAN function* (p=0.01) and -2.1 points in FIHOA* (p=0.03). Significant differences were also shown in SF-36* physical component scale and the VAS* patient global assessment. A significant reduction in synovitis was also demonstrated using ultrasound.1

"Our study provides evidence that local inflammation is a suitable target for drug treatment in hand osteoarthritis," said FĂ©line Kroon, Leiden University Medical Center, Leiden, The Netherlands. "Significant improvements in pain and function were seen in the trial meaning prednisolone could be considered by physicians treating people suffering with hand osteoarthritis."

The study was a randomised, double-blind, placebo-controlled trial of 92 patients with painful (fulfilling American College of Rheumatology criteria) and signs of synovial inflammation. Eligible patients were randomised to receive prednisolone 10mg daily for 6 weeks or placebo, followed by a two-week tapering scheme and six weeks without study medication. The mean age of patients was 63.9 years and 79% were women with baseline characteristics well-balanced between the groups. After tapering, all between group differences disappeared, and adverse events were mostly mild and comparable between groups.


Explore further

Zoledronic acid has no effect on knee pain or bone marrow lesions in knee OA after two years

Citation: Low-dose prednisolone significantly improves pain symptoms and function in hand osteoarthritis (2019, June 12) retrieved 16 June 2019 from https://medicalxpress.com/news/2019-06-low-dose-prednisolone-significantly-pain-symptoms.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
3 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more